Silvia Orengo-Nania, MD
Ophthalmology · Minneapolis, MNNPI 1861481228
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.3% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by NEW World Medical,inc. at 29.1% of the total. Reporting peaked in 2022 at $3,572 and has fallen 83.3% since, to $596 in 2025. Among ophthalmology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $86.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$3K
- Alcon$3K
- AbbVie$2K
- Sight Sciences, Inc.$1K
- Glaukos Corporation$912
- Aerie Pharmaceuticals, Inc.$265
- plus $772 from 7 others
What the payments were for
- Speaking & faculty fees$1,0009%
- Food & beverage$10,38690%
- Education$1201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 24 | $3,350 |
| Alcon | 34 | $2,717 |
| AbbVie(2 entities) | 45 | $2,458 |
| Sight Sciences, Inc. | 11 | $1,032 |
| Glaukos Corporation | 6 | $912 |
| Aerie Pharmaceuticals, Inc. | 2 | $265 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $224 |
| Bausch & Lomb Americas Inc. | 4 | $212 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $136 |
| Nova Eye, Inc. | 1 | $119 |
| Apellis Pharmaceuticals, Inc. | 1 | $36 |
| Beaver-visitec International, Inc. | 1 | $24 |
| Ocular Therapeutix, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$1,219
- Kahook Dual Blade$1,219
- XEN GLAUCOMA TREATMENT SYSTEM$922
- Hydrus Microstent$813
- Clareon$711
- OMNI(R) SURGICAL SYSTEM (US)$709
- Streamline Surgical System$632
- Clearpath$470
- Streamline$470
- Rhopressa$372
- iStent inject W$312
- VYZULTA$261
- Rocklatan$226
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$166
- iStent infinite Trabecular Micro-Bypass System Model iS3$166
- IACCESS$163
- AcrySof IQ VIVITY$132
- Tecnis IOL$125
- XEN$125
- MIEBO$125
How this compares
$11,506 in reported general payments places this provider in the 90th percentile of 330 ophthalmology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 97 | $59,710 |
| LumiganBimatoprost | 51 | $27,406 |
| Alphagan PBrimonidine Tartrate | 46 | $22,706 |
| RhopressaNetarsudil Mesylate | 29 | $20,277 |
| CombiganBrimonidine Tartrate/Timolol | 55 | $18,098 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 30 | $13,266 |
| Brimonidine Tartrate | 68 | $10,040 |
| VyzultaLatanoprostene Bunod | 14 | $9,282 |
| Latanoprost | 426 | $7,077 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $6,758 |
| Travoprost | 25 | $6,584 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 205 | $4,386 |
| Loteprednol Etabonate | 29 | $4,338 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 27 | $4,308 |
| Brinzolamide | 14 | $4,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $265 | $79,987126 claims |
| AbbVieLumigan, Alphagan P, Combigan | $2,458 | $68,211152 claims |
| AlconSimbrinza | $2,717 | $13,26630 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $212 | $9,28214 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $136 | $4,33829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 330 ophthalmology providers in Minnesota.
Other ophthalmology in Minneapolis
- Edwin RyanMinneapolis$9.6M
- David HardtenMinneapolis$119K
- Sandra MontezumaMinneapolis$48K
- Sundeep DevMinneapolis$13K
- Robert MittraMinneapolis$6K
- David ParkeMinneapolis$6K
- Michael LeeMinneapolis$3K
- Huda SheheitliMinneapolis$3K
- Dinesh GoyalMinneapolis$3K
- Mark LobanoffSt Louis Park$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.